Vanguard Group’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-13,139
| Closed | -$113K | – | 4455 |
|
|
2024
Q1 | $113K | Hold |
13,139
| – | – | ﹤0.01% | 4232 |
|
|
2023
Q4 | $46K | Sell |
13,139
-17,848
| -58% | -$62.8K | ﹤0.01% | 4380 |
|
|
2023
Q3 | $110K | Sell |
30,987
-6,167
| -17% | -$33.1K | ﹤0.01% | 4338 |
|
|
2023
Q2 | $216K | Buy |
37,154
+7,603
| +26% | +$139K | ﹤0.01% | 4302 |
|
|
2023
Q1 | $1.12M | Hold |
29,551
| – | – | ﹤0.01% | 3880 |
|
|
2022
Q4 | $881K | Buy |
29,551
+17
| +0.1% | +$514 | ﹤0.01% | 3949 |
|
|
2022
Q3 | $986K | Hold |
29,534
| – | – | ﹤0.01% | 4005 |
|
|
2022
Q2 | $1.18M | Hold |
29,534
| – | – | ﹤0.01% | 4023 |
|
|
2022
Q1 | $1.55M | Sell |
29,534
-4,997
| -14% | -$251K | ﹤0.01% | 4058 |
|
|
2021
Q4 | $1.91M | Sell |
34,531
-212
| -0.6% | -$13.5K | ﹤0.01% | 4057 |
|
|
2021
Q3 | $2.69M | Buy |
34,743
+291
| +0.8% | +$24.6K | ﹤0.01% | 3963 |
|
|
2021
Q2 | $4.47M | Sell |
34,452
-209
| -0.6% | -$28.9K | ﹤0.01% | 3660 |
|
|
2021
Q1 | $5.7M | Buy |
34,661
+19,094
| +123% | +$3.68M | ﹤0.01% | 3460 |
|
|
2020
Q4 | $3.64M | Buy |
15,567
+14,840
| +2,041% | +$2.07M | ﹤0.01% | 3491 |
|
|
2020
Q3 | $75K | Hold |
727
| – | – | ﹤0.01% | 4041 |
|
|
2020
Q2 | $29K | Hold |
727
| – | – | ﹤0.01% | 4052 |
|
|
2020
Q1 | $25K | Hold |
727
| – | – | ﹤0.01% | 4040 |
|
|
2019
Q4 | $34K | Sell |
727
-3,330
| -82% | -$219K | ﹤0.01% | 4065 |
|
|
2019
Q3 | $362K | Sell |
4,057
-342
| -8% | -$35.1K | ﹤0.01% | 3871 |
|
|
2019
Q2 | $598K | Sell |
4,399
-1,030
| -19% | -$163K | ﹤0.01% | 3798 |
|
|
2019
Q1 | $1.49M | Buy |
5,429
+643
| +13% | +$139K | ﹤0.01% | 3530 |
|
|
2018
Q4 | $603K | Buy |
4,786
+1,408
| +42% | +$382K | ﹤0.01% | 3693 |
|
|
2018
Q3 | $1.38M | Buy |
3,378
+5
| +0.1% | +$2.32K | ﹤0.01% | 3637 |
|
|
2018
Q2 | $1.82M | Buy |
3,373
+1,988
| +144% | +$1.06M | ﹤0.01% | 3528 |
|
|
2018
Q1 | $637K | Buy |
1,385
+217
| +19% | +$118K | ﹤0.01% | 3741 |
|
|
2017
Q4 | $783K | Buy |
1,168
+382
| +49% | +$231K | ﹤0.01% | 3664 |
|
|
2017
Q3 | $495K | Buy |
786
+87
| +12% | +$45.3K | ﹤0.01% | 3752 |
|
|
2017
Q2 | $336K | Sell |
699
-200
| -22% | -$122K | ﹤0.01% | 3801 |
|
|
2017
Q1 | $674K | Buy |
899
+78
| +10% | +$69.9K | ﹤0.01% | 3683 |
|
|
2016
Q4 | $805K | Sell |
821
-144
| -15% | -$165K | ﹤0.01% | 3627 |
|
|
2016
Q3 | $1.3M | Buy |
965
+12
| +1% | +$13.5K | ﹤0.01% | 3510 |
|
|
2016
Q2 | $835K | Buy |
953
+16
| +2% | +$21.2K | ﹤0.01% | 3653 |
|
|
2016
Q1 | $1.31M | Buy |
937
+198
| +27% | +$282K | ﹤0.01% | 3520 |
|
|
2015
Q4 | $1.37M | Buy |
739
+60
| +9% | +$120K | ﹤0.01% | 3527 |
|
|
2015
Q3 | $1.33M | Buy |
679
+577
| +566% | +$1.35M | ﹤0.01% | 3543 |
|
|
2015
Q2 | $231K | Buy |
+102
| New | +$239K | ﹤0.01% | 4023 |
|
Other funds holding TCON
Vanguard Group's TCON Position: Q2 2024 in Review
Vanguard Group sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 13,139 shares — an estimated $113K sold.
Vanguard Group first reported a position in TCON in Q2 2015 and held it in 36 quarters. The position peaked at $5.7M in Q1 2021. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.
- Vanguard Group reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Vanguard Group sold 13,139 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $113K.
- Vanguard Group first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2015 and held it in 36 quarters.
- Vanguard Group's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $5.7M in Q1 2021.
- 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.